Highest-materiality recent filing
Sharps Technology rebrands as SkyAI, pivots to AI finance platform for Global South
Company changed name to SkyAI, Inc.; new tickers SKYA (common) and SKYAW (warrants) effective May 28, 2026.
Sharps Technology enters 90-day lock-up with advisor SOL Markets; announces $100M buyback
SOL Markets voluntarily restricts sales of advisory warrants and underlying shares for 90 days, effective Jan 16, 2026.
Annemarie Tierney resigned as Independent Director and from Audit and Compensation Committees, effective Dec 19, 2025.
Sharps Technology authorizes $100M share repurchase program with Cantor Fitzgerald agent
Board approved up to $100M repurchase of common stock on October 2, 2025.
Sharps Technology authorizes $100M stock repurchase program, acquires 2M+ SOL tokens
Board authorized up to $100M stock repurchase of common shares in open market and negotiated transactions.
Sharps Technology settles litigation, transfers Safegard Medical Kft assets
Signed confidential settlement on Oct 6, 2025 with Barry Berler, Plastomold and affiliates, resolving all litigation claims.
Sharps Technology closes $410M private placement, launches Solana treasury; could raise up to $1B
Gross proceeds ~$410.9M from ~24.3M shares at $6.50 plus pre-funded/stapled warrants; additional $600M possible if all warrants exercised.
Sharps Technology enters $236.6M ATM equity offering with Cantor and Aegis
Up to $236,605,575 in common stock may be sold from time to time under the Sales Agreement.
Sharps Technology launches $400M crypto treasury offering, CEO resigns, shares increased
Raised ~$400M gross in a private placement of shares and warrants, both for cash and cryptocurrency (USDC/USDT or SOL tokens).
Issued 5 shares of Series B Preferred Stock to Executive Chairman Paul Danner for $100 total ($20/share) on July 17, 2025.
Sharps begins first commercial shipments; transitions to revenue-generating stage
Initiated shipments under three customer orders; first commercial revenue from $500K total purchase commitments.
Sharps Technology regains Nasdaq minimum bid price and equity compliance
Received Nasdaq notice confirming compliance with $1.00 minimum bid price and $2.5M equity requirements.
Purchase order of $100K from a Hungarian vaccine provider for SecureGard retractable syringes; first SecureGard order from this customer.
Sharps Technology receives $400K initial purchase order under $50M supply agreement
Initial $400K purchase order from U.S. leader in IV flushing solutions under July 2024 $50M, 5-year supply agreement.
Sharps Technology: 1-for-300 reverse stock split effective April 27, 2025
Reverse stock split 1:300 approved, effective at 11:59 p.m. ET on April 27, 2025.
Sharps Technology announces 1-for-300 reverse stock split effective April 27, 2025
Reverse split ratio 1-for-300, effective April 27, 2025 at 11:59 PM ET; post-split trading starts April 28.
Sharps Technology reports 97% of 2025 Series B Warrants exercised as of April 14
286,621,057 Class B cashless Warrants exercised, representing 97% of the 2025 Series B Warrants.
Sharps Technology receives Nasdaq deficiency notice for stockholders' equity below $2.5M requirement
Stockholders' equity of $1,996,129 as of Dec 31, 2024, below $2.5M minimum for continued listing.
Sharps Technology reports 199.8M Class B Warrants exercised as of April 2, 2025
199,765,734 Class B Warrants exercised in connection with January 29, 2025 public offering.
Sharps Technology shareholders reject reverse stock split; warrant issuance approved
Proposal for reverse stock split (1:3 to 1:11) failed: 3,442,858 for, 879,909 against; did not meet majority of outstanding shares.
Special shareholder meeting scheduled for March 28, 2025, to vote on reverse stock split proposal.
Sharps Tech gets Nasdaq delisting notice for bid price non-compliance; will appeal
Notified on March 12, 2025 for failing to maintain minimum $1.00 bid price for 30 consecutive days.
Sharps Technology closes $20M upsized public offering of units with warrants
Offering comprised 14,285,714 Common Units at $1.40/unit plus Pre-Funded Units at $1.3999.
Sharps Technology sells entire SecureGard inventory; secures multi-year production orders
Signed agreements with a European medical supply company covering Poland, Slovakia, Czech Republic for 1mL and 3mL SecureGard syringes.
Sharps Technology signs $50M+ SoloGard syringe deal; sets $5M 2025 revenue target
Entered $50M+ 5-year supply agreement for 500M SoloGard 10mL syringes with U.S. pharma company; deliveries begin Q1 2025.
Sharps Technology announces 1-for-22 reverse stock split effective Oct 15 to meet Nasdaq bid price
Reverse stock split at 1-for-22 ratio approved by stockholders on Oct 7, 2024.
Sharps Technology urges reverse split vote to avoid NASDAQ delisting by Oct 7 meeting
Special shareholder meeting scheduled for October 7, 2024 at 10:00 a.m. ET to vote on reverse stock split.
Sharps Technology completes $3.5M secured bridge financing with warrants
Gross proceeds of ~$3.5M from sale of $4.375M principal amount of senior secured notes and 5.7M shares/pre-funded warrants.
Sharps Technology secures Nasdaq continued listing pending shareholder vote on reverse split
Nasdaq granted continued listing subject to completion of a reverse stock split at a higher ratio.
Sharps Technology increases authorized common shares from 100M to 500M
Authorized common shares increased from 100 million to 500 million via Certificate of Amendment filed July 23, 2024.
Sharps Technology enters 5-year deal for 520M syringes, selling out EU facility capacity
5-year supply agreement with Stericare Solutions for 520M units of 10mL SoloGard syringes.
Sharps Technology faces Nasdaq delisting, shareholders approve reverse split and share increase
Nasdaq notified Sharps Technology of non-compliance due to bid price below $1.00 for 30 consecutive days.
CEO Robert Hayes letter asks shareholders to vote on three proposals by July 12, 11:59 p.m. ET.
Special meeting on July 15, 2024; record date May 17; vote deadline 11:59 p.m. ET July 12.
Sharps Technology raises $1.18M through stock offering and warrant exercise
Issued 2,239,000 shares at $0.38/share for gross proceeds of $850,820.
Effective July 27, 2023, Alan Blackman resigned from the Board of Directors (the “Board”) of Sharps Technology, Inc. (the “Company’), including as Co-Chairman of the Board.
As of February 1, 2023, the Company and Barry Berler determined that Mr. Berler will no longer be deemed an Executive Officer.
On September 30, 2022, Sharps Technology, Inc. (the “Company”) entered into a formal employment agreement (the “Agreement”) with Andrew R. Crescenzo (age 65), who has been serving as the Company’s Chief Financial Officer (CFO) on a contract services basis for the last three years.
On April 15, 2022, Brenda Baird Simpson and Jason Monroe were elected to the Company’s board of directors.
On April 15, 2022, Brenda Baird Simpson and Jason Monroe were elected to the Company’s board of directors.
Max materiality 0.95 · Median 0.65 · Most common event other_material